# A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus

> **NCT01029795** · PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 38 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** LY2599506
- **DRUG:** Glyburide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01029795
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-02
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** Terminated due to nonclinical safety findings
- **Last updated:** 2011-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01029795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01029795, "A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01029795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*